Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers
09:47am, Wednesday, 05'th Jul 2023
Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead drug candidate REQORSA Immunogene therapy, in combina
Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA
09:31am, Wednesday, 28'th Jun 2023
Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Desi
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
01:05pm, Thursday, 01'st Jun 2023
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lun
Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting
08:06am, Friday, 26'th May 2023
Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combination with Tagrisso in late-stage non-small cell l
Penny Stocks To Buy? 10 Under $1 To Watch This Week
03:29pm, Wednesday, 19'th Apr 2023
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise
11:14am, Wednesday, 19'th Apr 2023
A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the company announced. Investors liked what they saw, as sh
Genprex encouraged by latest reports on novel tumor suppressor
11:06am, Tuesday, 18'th Apr 2023
Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functions as a novel tumor suppressor for glioblastoma. G
Genprex to Present at Bioprocessing Summit Conference
07:30am, Monday, 13'th Mar 2023
Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies AUSTIN, Texas , March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:
Genprex announces $4M direct offering with single, healthcare-focused institutional investor
09:12am, Monday, 27'th Feb 2023
Genprex Inc. said it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for gross proceeds of approximately $4 million.
Genprex (GNPX) Stock Moves on Promising Diabetes Treatment Data
10:05am, Thursday, 23'rd Feb 2023
Genprex (NASDAQ: GNPX ) stock is on the move Thursday after providing an update on a study of its diabetes treatment. That positive news comes from a trial of gene therapy for the treatment of Type 1
Genprex unveils groundbreaking data from primate study on its novel gene therapy to treat Type 1 diabetes at ATTD 2023 in Berlin
08:40am, Thursday, 23'rd Feb 2023
Genprex, Inc. (NASDAQ:GNPX) has announced that data highlighting the potential of its gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh
Genprex has an exciting gene therapy platform, Dawson James notes as it assigns Buy rating in initial coverage
01:03pm, Thursday, 02'nd Feb 2023
Gene-based therapy company Genprex, Inc (NASDAQ:GNPX) has caught the eye of research firm Dawson James, which has initiated coverage with a Buy rating and $3 target price on the stock. Genprex is an
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
06:16pm, Friday, 06'th Jan 2023 Benzinga
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
Spruce Biosciences, Inc. (NASDAQ: SPRB) shares jumped 100.8%
Genprex signs exclusive license to additional diabetes technology with University of Pittsburgh
07:53am, Thursday, 05'th Jan 2023
Genprex, Inc. (NASDAQ:GNPX) told investors it has entered into an exclusive license agreement with the University of Pittsburgh, granting the company a worldwide, exclusive license to a patent applic
